Please assess the completion status of the following clinical trial:

Trial Title: Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histopathological proven prostate adenocarcinoma.~2. Rising prostate specific antigen (PSA) after definitive therapy with prostatectomy or radiation therapy (external beam or brachytherapy).~   1. Post radical prostatectomy (RP) - according to American Urological Association (AUA) recommendation criteria: PSA greater than 0.2 ng/mL measured more than 6 weeks after RP and confirmatory persistent PSA greater than 0.2 ng/mL.~  2. Post-radiation therapy - according to ASTRO-Phoenix consensus definition: Nadir + greater than or equal to 2 ng/mL rise in PSA.~3. Karnofsky performance status of ≥ 50.~4. Age ≥ 18.~5. Ability to understand a written informed consent document, and the willingness to sign it.~Exclusion Criteria:~1. Current investigational therapy for prostate cancer.~2. Unable to lie flat, still or tolerate a PET/CT scan.~3. Prior history of a malignancy within the last 2 years, except skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized, and except superficial bladder cancer.~4. Prisoner.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patient participants (Type: EXPERIMENTAL): PET/CT imaging

Based on this trial design, predict the completion outcome and termination type (if applicable).